$ENOV

6 stories mentioning ENOVUpdated just now

Every FINWIRES story that references ENOV, newest first.

Top Midday Decliners

Alumis (ALMS) said Tuesday that a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population.Shares slumped nearly 59% as intraday trading volume catapulted to over 20.9 million from a daily average of about 1.3 million.Enovis (ENOV) has signed a binding offer to acquire eCential Robotics for 176 million euros ($204 million) in cash, plus up to 35 million euros in milestone payments, the company said Tuesday.BMO Capital adjusted the Enovis price target to $27 from $30, while maintaining its outperform rating.Shares dropped 10% as intraday trading volume climbed to over 1.9 million from a daily average of about 1.1 million.Cango (CANG) reported a Q2 loss from continuing operations late Monday while revenue more than halved.Shares slumped 22%, with intraday trading volume at over 419,000, versus a daily average of about 259,000.Price: $9.00, Change: $-12.81, Percent Change: -58.73%

$ALMS$CANG$ENOV

Wire3h ago

BMO Capital Adjusts Enovis Price Target to $27 From $30, Maintains Outperform Rating

Enovis (ENOV) has an average rating of buy and mean price target of $41.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $22.53, Change: $-2.07, Percent Change: -8.40%

$ENOV

Sectors26d ago

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Thursday afternoon, with the NYSE Healthcare Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) was up 0.4%.In corporate news, Emergent BioSolutions (EBS) shares dropped 30% after it cut its full-year guidance and announced an organizational restructuring plan.Becton, Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's Q3 results exceeded Wall Street's estimates amid revenue gains across all divisions. Its shares gained 3.5%.Enovis (ENOV) shares fell 13% after the company reported its results for fiscal Q2.Braveheart Bio (BRVE) shares surged 70% in its Nasdaq debut Thursday, after the company announced an upsized IPO of 21.25 million common shares late Wednesday.

$BDX$BRVE$EBS$ENOV

Sectors26d ago

Sector Update: Healthcare Stocks Fall in Afternoon Trading

Healthcare stocks were lower Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.5%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, Enovis (ENOV) shares fell 11% after the company reported its results for fiscal Q2.Becton, Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's Q3 results exceeded Wall Street's estimates amid revenue gains across all divisions. Its shares gained 4.7%.Braveheart Bio (BRVE) shares rose 67% in its Nasdaq debut Thursday, after the company announced an upsized IPO of 21.25 million common shares late Wednesday.

$BDX$BRVE$ENOV

Sectors26d ago

Sector Update: Healthcare

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) rose 0.1%.In corporate news, Enovis (ENOV) shares fell 11% after the company reported its results for fiscal Q2.

$ENOV

Wire117d ago

Enovis Shares Rise After Reporting Higher Fiscal Q1 Adjusted EPS, Net Sales, Reiterating Fiscal 2026 Guidance

Enovis (ENOV) shares were up more than 8% in early trading on Thursday after the company posted higher fiscal Q1 results and maintained its fiscal 2026 outlook.The company reported fiscal Q1 adjusted net income of $0.89 per diluted share, up from $0.65 a year earlier.Analysts polled by FactSet expected $0.81.Net sales for the quarter ended April 3 were $589.2 million, up from $558.8 million a year earlier.Analysts surveyed by FactSet expected $572 million.The company reaffirmed fiscal 2026 adjusted EPS guidance of $3.52 to $3.73. Analysts polled by FactSet expect $3.59.Enovis also reaffirmed fiscal 2026 revenue guidance of $2.31 billion to $2.37 billion. Analysts surveyed by FactSet expect $2.34 billion.Price: $26.15, Change: $+1.28, Percent Change: +5.15%

$ENOV

Track with the FINWIRES app suite

FolioX

Track ENOV in your portfolio

WheelAI

Analyze ENOV options with the wheel strategy

StockInsider

See market sentiment on ENOV